Inventor · disambiguated record
Markus Ahlheim
Also filed as: AHLHEIM MARKUS
9 granted patents·24 pending applications·50 citations·filing 1993–2024
87Inventor score
Top patents by PatentIndex Score
33 records- 0190US2025205147A1Octreotide Depot Formulation with Constantly High Exposure LevelsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0289US2025082718A1Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymersNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0386US8815293B2Organic compoundsAHLHEIM MARKUS·Filed 2010·Granted Aug 26, 2014·9 cites·22 claims
- 0486US8614232B2Injectable depot formulation comprising crystals of iloperidoneWIECKHUSEN DIERK·Filed 2012·Granted Dec 24, 2013·5 cites·4 claims
- 0586US8293765B2Injectable depot formulation comprising crystals of iloperidoneWIECKHUSEN DIERK·Filed 2011·Granted Oct 23, 2012·5 cites·19 claims
- 0686US8227488B2Injectable depot formulation comprising crystals of iloperidoneWIECKHUSEN DIERK·Filed 2012·Granted Jul 24, 2012·10 cites·17 claims
- 0786US2024082148A1Octreotide Depot Formulation with Constantly High Exposure LevelsNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0881US2022296675A1Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymersNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0978US7767230B2Organic compoundsNOVARTIS AG·Filed 2002·Granted Aug 3, 2010·9 cites·16 claims
- 1076US2021161806A1Octreotide Depot Formulation with Constantly High Exposure LevelsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1171US2009099232A1Injectable depot formulation comprising crystals of iloperidoneWIECKHUSEN DIERK·Filed 2008·Application pending·0 cites
- 1271US2020206306A1Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymersNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1370US2010151033A1Octreotide depot formulation with constantly high exposure levelsNOVARTIS AG·Filed 2009·Application pending·0 cites
- 1470US2019209462A1Octreotide depot formulation with constantly high exposure levelsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1568US8999390B2Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymersPETERSEN HOLGER·Filed 2012·Granted Apr 7, 2015·2 cites·11 claims
- 1668US2011262545A1Octreotide depot formulation with constantly high exposure levelsAHLHEIM MARKUS·Filed 2009·Application pending·0 cites
- 1766US2018036230A1Octreotide depot formulation with constantly high exposure levelsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 1865US8188037B2Microparticles comprising somatostatin analoguesAHLHEIM MARKUS·Filed 2010·Granted May 29, 2012·1 cites·10 claims
- 1964US2018140662A1Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide PolymersNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2064US2017143791A1Octreotide depot formulation with constantly high exposure levelsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2164US2014363513A1Octreotide Depot Formulation with Constantly High Exposure LevelsAHLHEIM MARKUS·Filed 2014·Application pending·0 cites
- 2262US2009004283A1Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide PolymersNIVARTUS AG·Filed 2006·Application pending·0 cites
- 2359US2016089336A1Octreotide depot formulation with constantly high exposure levelsAHLHEIM MARKUS·Filed 2015·Application pending·0 cites
- 2459US2005250813A1Injectable depot formulation comprising crystals of iloperidoneWIECKHUSEN DIERK·Filed 2003·Application pending·0 cites
- 2559US2015037420A1Sustained Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide PolymersPETERSEN HOLGER·Filed 2014·Application pending·0 cites
- 2656US7759308B2Microparticles comprising somatostatin analoguesNOVARTIS AG·Filed 2004·Granted Jul 20, 2010·0 cites·11 claims
- 2756US2013122064A1Ophthalmic Depot Formulations for Periocular or Suconjunctival AdministrationNOVARTIS AG·Filed 2013·Application pending·0 cites
- 2853US2016120935A1Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide PolymersPETERSEN HOLGER·Filed 2015·Application pending·0 cites
- 2953US2011003002A1Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymersPETERSEN HOLGER·Filed 2009·Application pending·0 cites
- 3051US5334710ACompounds having non-linear optical propertiesSANDOZ LTD·Filed 1993·Granted Aug 2, 1994·9 cites·9 claims
- 3151US2006189683A1Parenteral formulation of mycophenolic acid, a salt or prodrug thereofAHLHEIM MARKUS·Filed 2004·Application pending·0 cites
- 3247US2012214749A1Microparticles comprising somatostatin analoguesAHLHEIM MARKUS·Filed 2012·Application pending·0 cites
- 3343US2010266704A1Octreotide depot formulation with constantly high exposure levelsNOVARTIS AG·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Markus Ahlheim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →